急性ST段抬高型心肌梗死患者淋巴细胞/单核细胞比值与无复流及短期预后的相关性

doi:10.19739/j.cnki.issn1001-9510.2021.04.003

Abstract
Figure/Table
References
Related Citation (5)

Download: PDF (982 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To assess the correlation between lymphocyte/monocyte ratio (LMR) and no-reflow (NRP) and in-hospital major adverse cardiovascular events after primary coronary intervention (PPCI) in patients with ST-segment elevation myocardial infarction.Methods One hundred and thirty-nine patients with acute ST-segment elevation myocardial infarction were included in this study. The patients were divided into the NRP group (n=25) and the control group (n=114) according to thrombolytic therapy for myocardial infarction (TIMI) blood flow grade. No reflow was defined as TIMI ≤ 2 and the control group as TIMI 3. The risk factors of NRP were analyzed and the application value of LMR was evaluated in the prediction of NRP patients and in-hospital major adverse cardiovascular events (MACE).Results Compared with those in the control group, the lymphocyte count and LMR value in the NRP group were lower; the incidence of coronary residual thrombosis signs, the use rate of teicoplanin, and in-hospital MACE after balloon dilatation were higher in the NRP group, and the differences were statistically significant (P<0.05); the results of multivariate logistic regression analysis showed that the lymphocyte count rise could increase the risk of NRP after PPCI in STEMI patients, and the LMR rise could reduce the risk of NRP. The patients were divided into two groups according to the LMR value of 2.815, and the incidence of MACE was higher in the low LMR group.Conclusion The lymphocyte count rise was independent risk factors for NRP, and the LMR rise was the protective factor for NRP. LMR also has some predictive value for MACE during hospitalization.

Key words： acute myocardial infarction lymphocyte/monocyte ratio PCI no-reflow phenomenon short-term prognosis

Received: 09 March 2021

PACS:

R543.3

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WANG Shuai
	ZHAO Kai
	HE Guanglei
	LIU Xianliang

Cite this article:

WANG Shuai,ZHAO Kai,HE Guanglei, et al. Correlation between lymphocyte/monocyte ratio and no-reflow and short-term prognosis in patients with acute ST-segment elevation myocardial infarction[J]. 滨州医学院学报, 2021, 44(4): 252-256.

URL:

http://manu58.magtech.com.cn/Jwk_bzyxy/EN/10.19739/j.cnki.issn1001-9510.2021.04.003 OR http://manu58.magtech.com.cn/Jwk_bzyxy/EN/Y2021/V44/I4/252

[1] HARRISON R W, AGGARWAL A, OU F S, et al. Incidence and outcomes of no-reflow phenomenon during percutaneous coronary intervention among patients with acute myocardial infarction[J]. Am J Cardiol, 2013, 111(2): 178-184.
[2] MAGRO M, NAUTA S T, SIMSEK C, et al. Usefulness of the SYNTAX score to predict “no reflow” in patients treated with primary percutaneous coronary intervention for ST-segment elevation myocardial infarction[J]. Am J Cardiol, 2012, 109(5): 601-606.
[3] NDREPEPA G, TIROCH K, FUSARO M, et al. 5-year prognostic value of no-reflow phenomenon after percutaneous coronary intervention in patients with acute myocardial infarction[J]. J Am Coll Cardiol, 2010, 55(21): 2383-2389.
[4] 赵倩,赵刚.急性心肌梗死患者经皮冠状动脉介入治疗中无复流现象预测指标及防治策略的研究进展[J].实用心脑肺血管病杂志,2019,27(7):1-4.
[5] KIRIS T, ELIK A, VARIŞ E, et al. Association of lymphocyte-to-monocyte ratio with the mortality in patients with ST-elevation myocardial infarction who underwent primary percutaneous coronary intervention[J]. Angiology, 2017, 68(8): 707-715.
[6] WANG Q, MA J, JIANG Z, et al. Association of lymphocyte-to-monocyte ratio with in-hospital and long-term major adverse cardiac and cerebrovascular events in patients with ST-elevated myocardial infarction[J]. Medicine (Madr), 2017, 96(34): e7897.
[7] KOSE N, AKIN F, YILDIRIM T, et al. The association between the lymphocyte-to-monocyte ratio and coronary artery disease severity in patients with stable coronary artery disease[J]. Eur Rev Med Pharmacol Sci, 2019, 23(6): 2570-2575.
[8] SILVA N, BETTENCOURT P, GUIMARAES J T. The lymphocyte-to-monocyte ratio: An added value for death prediction in heart failure[J]. Nutr Metab Cardiovasc Dis, 2015, 25(11): 1033-1040.
[9] 贺威,范继红,靳志涛,等.急性ST段抬高型心肌梗死患者入院早期中性粒细胞/淋巴细胞比值与院内主要不良心血管事件的相关性[J].中国循环杂志,2016,31(1):36-39.
[10] WANG Z, REN L, LIU N, et al. Association of monocyte count on admission with angiographic no-reflow after primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction[J]. Kardiol Pol, 2016, 74(10): 1160-1166.
[11] WIDMER A, LINKA A Z, ATTENHOFER JOST C H, et al. Mechanical complications after myocardial infarction reliably predicted using C-reactive protein levels and lymphocytopenia[J]. Cardiology, 2003, 99(1): 25-31.
[12] DRAGU R, HURI S, ZUKERMANN R, et al. Predictive value of white blood cell subtypes for long-term outcome following myocardial infarction[J]. Atherosclerosis, 2008, 196(1): 405-412.
[13] THAM T, OLSON C, KHAYMOVICH J, et al. The lymphocyte-to-monocyte ratio as a prognostic indicator in head and neck cancer: a systematic review and meta-analysis [J]. European archives of oto-rhino-laryngology: official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2018, 275(7): 1663-1670.
[14] 牛俊颖,朱华渊,王莉,等.淋巴细胞/单核细胞比值在血管免疫母细胞性T细胞淋巴瘤患者中的预后价值[J].中华血液学杂志,2018,39(4):265-270.
[15] GARY T, PICHLER M, BELAJ K, et al. Lymphocyte-to-monocyte ratio: A novel marker for critical limb ischemia in PAOD patients[J]. Int J Clin Pract, 2014, 68(12): 1483-1487.
[16] SI Y, LIU J, SHAN W, et al. Association of lymphocyte-to-monocyte ratio with total coronary plaque burden in patients with coronary artery disease[J]. Coron Artery Dis, 2020, 31(7): 650-655.
[17] GONG S, GAO X, XU F, et al. Association of lymphocyte to monocyte ratio with severity of coronary artery disease[J]. Medicine (Madr), 2018, 97(43): e12813.